Monomethyl fumarate

Generic Name: Monomethyl fumarate

Brand Names: Bafiertam

Drug Type: Small Molecule

Chemical Formula: C_₅H_₆O_₄

CAS Number: 2756-87-8

Unique Ingredient Identifier: 45IUB1PX8R

Clinical Trials

Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors

Phase 1

Not yet recruiting

Conditions: Myelodysplastic Syndromes
Acute Leukemia
Severe Aplastic Anemia

Interventions: Drug: Sirolimus
Drug: Abatacept
Drug: MMF
Drug: ATG

First Posted Date: 2024-02-28

Last Posted Date: 2024-03-21

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 6

Registration Number: NCT06279494

A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation

Phase 2

Active, not recruiting

Conditions: Liver Transplantation

Interventions: Biological: TCD601
Biological: Cyclophosphamide
Drug: TAC
Drug: MMF
Drug: Corticosteroids

First Posted Date: 2023-08-31

Last Posted Date: 2024-11-27

Lead Sponsor: ITB-Med LLC

Target Recruit Count: 12

Registration Number: NCT06019507

Locations: 🇸🇪
Karolinska University Hospital, Stockholm, Huddinge, Sweden

Observational Study of Persistence on Bafiertam Treatment in Routine Clinical Practice

Terminated

Conditions: Relapsing Remitting Multiple Sclerosis

First Posted Date: 2023-08-07

Last Posted Date: 2025-03-06

Lead Sponsor: Banner Life Sciences LLC

Target Recruit Count: 25

Registration Number: NCT05978531

Locations: 🇺🇸
Gilbert Neurology, Gilbert, Arizona, United States
🇺🇸
Regina Berkovich MD PhD Inc., West Hollywood, California, United States
🇺🇸
Comprehensive Neurology Clinics of Bethesda Mid-Atlantic Epilepsy and Sleep Center, Bethesda, Maryland, United States

and more 7 locations

Mycophenolate Mofetil in Gastrointestinal Henoch-Schonlein Purpura

Not Applicable

Recruiting

Conditions: Henoch-Schönlein Purpura
Mycophenolate Mofetil
Gastrointestinal Injury

Interventions: Drug: MMF

First Posted Date: 2023-07-19

Last Posted Date: 2023-07-19

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 24

Registration Number: NCT05951517

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

Use of Baricitenib to Maintain of Remission

Phase 2

Recruiting

Conditions: Nephritis
Lupus or SLE

Interventions: Drug: MMF
Drug: Baricitinib 4 MG
Drug: Baricitinib 2 MG

First Posted Date: 2023-01-17

Last Posted Date: 2023-01-17

Lead Sponsor: Assiut University

Target Recruit Count: 80

Registration Number: NCT05686746

Locations: 🇪🇬
Manal Hassanien, Assiut, Yes, Egypt

A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome

Phase 3

Active, not recruiting

Conditions: Childhood Idiopathic Nephrotic Syndrome

Interventions: Drug: Obinutuzumab
Drug: MMF
Drug: Prednisone
Drug: Methylprednisolone
Drug: Acetaminophen/ Paracetamol
Drug: Diphenhydramine Hydrochloride

First Posted Date: 2022-11-25

Last Posted Date: 2025-04-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 80

Registration Number: NCT05627557

Locations: 🇫🇷
CHU de Nice, Nice, Alpes-Maritimes, France
🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Lucile Packard Children's Hospital - Stanford, Palo Alto, California, United States

and more 55 locations

KidneyCare Immuno-optimization in Renal Allografts (KIRA)

Not Applicable

Withdrawn

Conditions: Kidney Transplant
Allograft
Immunosuppression

Interventions: Diagnostic Test: KidneyCare
Drug: steroid
Drug: MMF

First Posted Date: 2022-06-21

Last Posted Date: 2023-03-27

Lead Sponsor: CareDx

Registration Number: NCT05423496

Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ALXN2050
Drug: Cyclosporine
Drug: MMF
Drug: Tacrolimus

First Posted Date: 2022-01-21

Last Posted Date: 2023-04-04

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 61

Registration Number: NCT05202145

Locations: 🇺🇸
Clinical Study Site, Tempe, Arizona, United States

Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® From Dimethyl Fumarate

Withdrawn

Conditions: Relapsing Remitting Multiple Sclerosis

First Posted Date: 2021-06-14

Last Posted Date: 2021-11-18

Lead Sponsor: Banner Life Sciences LLC

Registration Number: NCT04925778

A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis

Phase 3

Active, not recruiting

Conditions: Lupus Nephritis

Interventions: Drug: Obinutuzumab
Drug: MMF
Drug: Prednisone
Drug: Placebo
Drug: Methylprednisolone
Drug: Acetaminophen
Drug: Diphenhydramine

First Posted Date: 2020-01-09

Last Posted Date: 2025-04-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 271

Registration Number: NCT04221477

Locations: 🇮🇹
A.O. Spedali Civili Di Brescia-P.O. Spedali Civili, Brescia, Lombardia, Italy
🇵🇪
Clínica San Juan Bautista CSJB, Lima, Peru
🇺🇸
NYU Langone Medical Center, New York, New York, United States

and more 70 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy